Nicox: NCX 470 data presentation at the 2026 AAOpt Congress

Nicox SA, a company specializing in ophthalmology, announces the presentation of key data on NCX 470 at the 2026 Annual Meeting of the American Academy of Optometry (AAOpt) in Anaheim, California. This new therapeutic agent, designed to reduce intraocular pressure, has completed a Phase 3 clinical program. The meeting will provide an opportunity to share these significant results with the optometry community, which is crucial in the management of glaucoma.

Two presentations are planned: one on the comparative efficacy of NCX 470 and Latanoprost for open-angle glaucoma, and the other on aqueous humor dynamics, detailing a Phase 3b clinical trial. Nicox will also participate in other major conferences during the second half of 2026.